Getinge Beheer

Beheer criteriumcontroles 3/4

De CEO Getinge's is Mattias Perjos, benoemd in Mar2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 46.39M, bestaande uit 55.9% salaris en 44.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.037% van de aandelen van het bedrijf, ter waarde € 1.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 7.6 jaar.

Belangrijke informatie

Mattias Perjos

Algemeen directeur

SEK 46.4m

Totale compensatie

Percentage CEO-salaris	55.9%
Dienstverband CEO	7.6yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	7.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mattias Perjos's beloning veranderd ten opzichte van Getinge's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	SEK 2b
Jun 30 2024	n/a	n/a	SEK 3b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 46m	SEK 26m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 2b
Jun 30 2023	n/a	n/a	SEK 2b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 43m	SEK 24m	SEK 2b
Sep 30 2022	n/a	n/a	SEK 3b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 60m	SEK 23m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 4b
Mar 31 2021	n/a	n/a	SEK 4b
Dec 31 2020	SEK 67m	SEK 23m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 2b
Mar 31 2020	n/a	n/a	SEK 1b
Dec 31 2019	SEK 46m	SEK 22m	SEK 1b
Sep 30 2019	n/a	n/a	SEK 1b
Jun 30 2019	n/a	n/a	-SEK 632m
Mar 31 2019	n/a	n/a	-SEK 654m
Dec 31 2018	SEK 34m	SEK 21m	-SEK 967m
Sep 30 2018	n/a	n/a	-SEK 727m
Jun 30 2018	n/a	n/a	SEK 847m
Mar 31 2018	n/a	n/a	SEK 676m
Dec 31 2017	SEK 26m	SEK 15m	SEK 1b

Compensatie versus markt: De totale vergoeding ($USD 4.41M ) Mattias } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.32M ).

Compensatie versus inkomsten: De vergoeding van Mattias is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mattias Perjos (52 yo)

7.6yrs

Tenure

SEK 46,388,000

Compensatie

Mr. Mattias Perjos, M. Sc., serves as Independent Director at Euroapi S. A. since January 11, 2023. He has been the Chief Executive Officer and President at Getinge AB since March 27, 2017. Mr. Perjos serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mattias Perjos	CEO, President & Director	7.6yrs	SEK 46.39m	0.037% € 1.7m
Agneta Palmer	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Lars Mattsson	Head of Investor Relations	no data	geen gegevens	geen gegevens
Anna Romberg	Executive Vice President of Sustainability	4yrs	geen gegevens	0.0026% € 123.8k
Magnus Lundback	Executive Vice President of Human Resources	7.8yrs	geen gegevens	0.0014% € 66.9k
Carsten Blecker	Chief Commercial Officer	6.8yrs	geen gegevens	0.0018% € 87.3k
Stephane Roy	President of Surgical Workflows	5.9yrs	geen gegevens	0.0014% € 66.4k
Eric Honroth	President of Life Science	no data	geen gegevens	0.000060% € 2.8k
Patricia Fitch	President of North America Region	2.5yrs	geen gegevens	geen gegevens
Elin Frostehav	President of Acute Care Therapies	2.5yrs	geen gegevens	0.00032% € 15.2k
Joanna Engelke	Executive VP of Quality Compliance	2yrs	geen gegevens	geen gegevens
Avril Forde	President of Maquet Ltd & Maquet Ireland	8.8yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GTN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mattias Perjos	CEO, President & Director	7.6yrs	SEK 46.39m	0.037% € 1.7m
Johan Bygge	Independent Director	17.5yrs	SEK 972.90k	0.0076% € 360.4k
Carl Bennet	Non-Independent Vice Chairman	35.8yrs	SEK 781.43k	geen gegevens
Malin Persson	Independent Director	10.8yrs	SEK 781.43k	0.0030% € 141.3k
Johan Malmquist	Independent Chairman	8.6yrs	SEK 1.73m	0.044% € 2.1m
Cecilia Wennborg	Independent Director	14.5yrs	SEK 969.80k	0.0046% € 217.7k
Ake Larsson	Employee Representative Director	2yrs	geen gegevens	geen gegevens
Dan Frohm	Non-Independent Director	7.6yrs	SEK 928.40k	0.056% € 2.6m
Fredrik Brattborn	Employee Representative Director	2.5yrs	geen gegevens	geen gegevens
Kristian Samuelsson	Independent Director	3.5yrs	SEK 819.72k	0.0018% € 87.3k
Pontus Kall	Deputy Director	no data	geen gegevens	geen gegevens
Ida Ekman	Deputy Director	2yrs	geen gegevens	0.000020% € 948.5

7.6yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GTN wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).

Getinge Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought €98k worth of stock

Independent Chairman recently bought €375k worth of stock

Getinge Announces CFO Changes

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Recent updates

Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)

Independent Director recently bought €98k worth of stock

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought €375k worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)

New minor risk - Share price stability

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Investor sentiment deteriorates as stock falls 17%

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Dividend of kr4.40 announced

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Third quarter 2023 earnings released

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Second quarter 2023 earnings released

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Investor sentiment deteriorates as stock falls 16%

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

First quarter 2023 earnings released

Now 23% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Investor sentiment deteriorated over the past week

Getinge Revises Net Sales Guidance for the Full Year 2022

Independent Chairman recently bought €281k worth of stock

Insufficient new directors

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Upcoming dividend of kr4.00 per share

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)

Insufficient new directors

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Chief Commercial Officer recently bought €56k worth of stock

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)

Getinge AB Provides Sales Guidance for the Year 2021

Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency

Chief Commercial Officer recently bought €27k worth of stock

Chief Commercial Officer recently bought €27k worth of stock

First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020)

Director has left the company

Upcoming dividend of kr3.00 per share

Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019)

Getinge AB Proposes Dividend, Payable on April 27, 2021

Getinge AB and University of Gothenburg Initiates Strategic Research Partnership